|
|
|
| The Efficacy of Milrinone Combined with rhBNP in the Treatment of Chronic Heart Failure and its Impact on Heart and Lung Function of Patients |
| QUAN Dangjun, ZHANG Mingbu, ZHAO Xiangli |
| Department of Cardiovascular Medicine, Weinan Central Hospital,Weinan Shaanxi 714000 |
|
|
|
|
Abstract 【Objective】To explore the therapeutic effect of milrinone combined with recombinant human brain natriuretic peptide (rhBNP) in the treatment of chronic heart failure and its impact on the heart and lung function of patients.【Methods】A retrospective analysis was conducted on the clinical data of 120 patients with chronic heart failure admitted to our hospital from October 2021 to October 2022. According to the quality method, they were divided into the observation group (treated with milrinone combined with rhBNP) and the control group (treated with milrinone), with 60 cases in each group. We compared the treatment effects and adverse reactions between two groups, and also compared the heart function indicators [cardiac output (CO), stroke output (SV), left ventricular ejection fraction (LVEF)], lung function indicators [percentage of forced expiratory volume at 1 second to expected value (FEV1%), forced lung activity percentage to expected value (FVC%), FEV1/FVC], as well as serum BNP and uric acid (UA) levels before and after treatment.【Results】The total effective rate of the observation group was significantly higher than that of the control group (P<0.05). After treatment, the CO, SV, and LVEF of the two groups were higher than before treatment, and the observation group was higher than the control group, with statistical significance (P<0.05). After treatment, the FEV1%, FVC%, and FEV1/FVC of the two groups were higher than before treatment, and the observation group was higher than the control group, with statistical significance (P<0.05). After treatment, the serum BNP and UA levels in both groups were lower than before treatment, and the observation group was lower than the control group (P<0.05). There was no statistically significant difference in the total incidence of adverse reactions between the two groups (P>0.05).【Conclusion】The combination of milrinone and rhBNP is safe and effective in treating chronic heart failure, and can improve the heart and lung function of patients, which is worth clinical reference.
|
|
Received: 15 February 2023
|
|
|
|
|
|
[1] 夏勇, 张建卿, 王少霞,等. 沙库巴曲缬沙坦联合琥珀酸美托洛尔缓释片治疗冠状动脉粥样硬化性心脏病并慢性心力衰竭的效果观察[J].首都医科大学学报, 2020, 41(1):113-118.
[2] 李江, 曹佳宁, 刘文娴,等. 沙库巴曲缬沙坦治疗老年人扩张型心肌病致慢性心力衰竭的疗效观察[J].中华老年医学杂志, 2019, 38(5):520-524.
[3] 梁可建, 谭志伟, 李泽茂. 米力农注射液治疗老年患者慢性心力衰竭的效果及对心功能和NT-proBNP水平的影响[J].黑龙江医药, 2021, 34(6):1305-1307.
[4] 蔚华. 重组人脑利钠肽联合沙库巴曲缬沙坦治疗心力衰竭患者的临床疗效[J].中国药物与临床, 2021, 21(8):1372-1373.
[5] 刘锐棠, 钟微子. 重组人脑利钠肽与米力农治疗难治性心力衰竭的疗效观察[J].实用心脑肺血管病杂志, 2012, 20(2):199-200.
[6] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 慢性心力衰竭诊断治疗指南[J].中华心血管病杂志, 2007, 35(12):1076-1095.
[7] 李志广, 马高峰, 王雪,等. 左卡尼汀联合阿托伐他汀钙治疗慢性心力衰竭的疗效及对心功能和血清CRP、IL-6、TNF-α水平的影响[J].中西医结合心脑血管病杂志, 2018, 16(3):323-326.
[8] 曹明善, 王春娣, 胡小倩,等. 正五聚蛋白3和心型脂肪酸结合蛋白及肌酸激酶同工酶水平与慢性心力衰竭患者治疗效果的关系及对心血管事件发生的预测研究[J].中国心血管病研究, 2022, 20(6):537-541.
[9] JENTZER J C,CHONDE M D,DEZFULIAN C. Myocardial dysfunction and shock after cardiac arrest[J].Biomed Res Int,2015, 20(7):632-639.
[10] 张庆礼, 凌涛, 孙大勇. rhBNP联合米力农治疗慢性肺心病心力衰竭的疗效及对心肺功能和甲状腺激素水平的影响[J].海南医学, 2022, 33(12):1512-1515.
[11] 梁卫章, 赵利平, 石建平,等. 冻干重组人脑利钠肽治疗冠心病心力衰竭疗效及对血流动力学、尿量、心肾功能的影响[J].现代中西医结合杂志, 2021, 30(20):2236-2238.
[12] 梁雁翎, 迟增鑫, 魏勇,等. rhBNP结合米力农对慢性肺心病合并心力衰竭患者心肺功能及血清甲状腺激素水平的影响[J].中国老年学杂志, 2021, 41(7):1345-1349.
[13] 江永进, 冯俊, 张静,等. Hcy、BNP、CRP联合检测对慢性心力衰竭病人诊断的临床价值[J].中西医结合心脑血管病杂志, 2020, 18(17):2836-2838.
[14] 蔡燕娟, 陈权, 何厚洪. 射血分数保留性心力衰竭病人超声心动图特征及心功能分级与血UA、NT-proBNP的关系[J].中西医结合心脑血管病杂志, 2021, 19(10):1703-1706.
[15] 张丽伟. 慢性心力衰竭患者血清尿酸、N末端B型利钠肽原、血管形成抑制素-2与左心室射血分数的相关性[J].实用临床医药杂志, 2020, 24(12):29-31.
[16] 王林华, 李小静, 常建航. 氟伐他汀联合重组人脑利钠肽对老年慢性心力衰竭患者心功能及PS、UA水平的影响[J].中国老年学杂志, 2022, 42(9):2060-2064. |
| [1] |
. [J]. JOURNAL OF CLINICAL RESEARCH, 2024, 41(6): 907-909. |
|
|
|
|
2024, Vol. 41 
